1-6 of 6
James R Mason, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

RNF5 Defines Acute Myeloid Leukemia Growth and Susceptibility to Histone Deacetylase Inhibitors

Ali Khateb, PhD, Anagha Deshpande, PhD, Yongmei Feng, PhD, Ikrame Lazar, PhD, Joo Sang Lee, PhD, Bertrand Fabre, PhD, Yan Li, PhD, Darren Finlay, PhD, Yu Fujita, PhD, Tongwu Zhang, PhD, Ian Pass, PhD, Ido Livneh, PhD, Carol Burian, James R. Mason, MD, Ronit Almog, MD, Nurit Horesh, MD, Yishai Ofran, MD, Kevin Brown, Kristiina Vuori, PhD, Michael Jackson, PhD, Eytan Ruppin, PhD, Aniruddha J. Deshpande, PhD, Ze'ev A. Ronai, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 31–32.
https://doi.org/10.1182/blood-2020-143352
Published: 2020
Journal Articles

Optical Mapping Uncovers Multiple Novel Genomic Structural Variants in Patient Leukemias

Darren Finlay, PhD, Rabi Murad, Karl Hong, Joyce Lee, Andy Pang, PhD, Chi-Yu Lai, Carol Burian, James R. Mason, MD, Alex Hastie, PhD, Jun Yin, Kristiina Vuori, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 33–34.
https://doi.org/10.1182/blood-2020-143175
Published: 2020
Journal Articles

ABO/Rh Blood Group and COVID-19 Infection Severity

David J Hermel, MD, Elisa Quiroz, MD, Samantha R Bagsic, PhD, Carrie L. Costantini, MD, Alan Saven, MD, James R. Mason, MD, Zhubin Gahvari, MD, Emily Nagler, MD, Kathryn Bollin, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 20–21.
https://doi.org/10.1182/blood-2020-141702
Published: 2020
Journal Articles

Ongoing Study of Obinutuzumab Short Duration Infusion in Patients with Previously Untreated Advanced Follicular Lymphoma

Miguel A Canales, MD PhD, Thomas A Buchholz, MD, James R Mason, MD, Joana M Parreira, MD, Monique S Tomiczek, MSc, Kai Hübel, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5269.
https://doi.org/10.1182/blood-2019-123638
Published: 2019
Journal Articles

Clinical Trial of Therapeutic Blockade of CTLA4 with Ipilimumab in Patients with Relapse of Malignancy Following Allogeneic Hematopoietic Transplantation.

Asad Bashey, MD, PhD, Bridget Medina, Sue Corringham, RN, Mildred Pasek, Ewa Carrier, MD, Linda Vrooman, RN, Howard Streicher, MD, Israel Lowy, MD, Scott R. Solomon, MD, Lawrence E. Morris, MD, Kent Holland, MD, James R. Mason, MD, Robert J. Soiffer, MD, Edward D. Ball, MD
Journal: Blood
Blood (2007) 110 (11): 1646.
https://doi.org/10.1182/blood.V110.11.1646.1646
Published: 2007
Journal Articles

Phase I Study of Ipilimumab (Neutralizing Monoclonal Anti-CTLA4 Antibody) To Treat Relapse of Malignancy after Allogeneic Hematopoietic Stem Cell Transplantation: Evidence of Tumor Regression without Induction of GVHD.

Asad Bashey, MD, PhD, Bridget Medina, Sue Corringham, RN, Mildred Pasek, RN, Ewa Carrier, MD, Howard Streicher, MD, Israel Lowy, MD, James R. Mason, MD, Robert J. Soiffer, MD, Edward D. Ball, MD
Journal: Blood
Blood (2006) 108 (11): 410.
https://doi.org/10.1182/blood.V108.11.410.410
Published: 2006